{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:33:25Z","timestamp":1754159605066,"version":"3.41.2"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"DOI":"10.7759\/cureus.88751","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T17:24:39Z","timestamp":1753464279000},"source":"Crossref","is-referenced-by-count":0,"title":["Triple-Negative Metaplastic Breast Cancer Ameliorated Following KEYNOTE-522: A Case Report"],"prefix":"10.7759","author":[{"given":"Edoardo G","family":"Frezza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayatri D","family":"Nimmagadda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olutayo","family":"Sogunro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3100","article-title":"Molecular characterization and prospective evaluation of pathologic response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer","volume":"28","author":"Yam C","year":"2022","unstructured":"Yam C, Abuhadra N, Sun R, et al.. Molecular characterization and prospective evaluation of pathologic response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res. 2022, 28:2878-89. 10.1158\/1078-0432.CCR-21-3100","journal-title":"Clin Cancer Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0398","article-title":"Early and locally advanced metaplastic breast cancer: presentation and survival by receptor status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014","volume":"23","author":"Schroeder MC","year":"2018","unstructured":"Schroeder MC, Rastogi P, Geyer CE Jr, Miller LD, Thomas A. Early and locally advanced metaplastic breast cancer: presentation and survival by receptor status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014. Oncologist. 2018, 23:481-8. 10.1634\/theoncologist.2017-0398","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103924","article-title":"Metaplastic breast cancer: a review","volume":"182","author":"Thomas HR","year":"2023","unstructured":"Thomas HR, Hu B, Boyraz B, Johnson A, Bossuyt VI, Spring L, Jimenez RB. Metaplastic breast cancer: a review. Crit Rev Oncol Hematol. 2023, 182:103924. 10.1016\/j.critrevonc.2023.103924","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple\u2011negative breast cancer therapy: current and future perspectives (Review)","volume":"57","author":"Won KA","year":"2020","unstructured":"Won KA, Spruck C. Triple\u2011negative breast cancer therapy: current and future perspectives (Review). Int J Oncol. 2020, 57:1245-61. 10.3892\/ijo.2020.5135","journal-title":"Int J Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00302-z","article-title":"Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma","volume":"7","author":"Wong W","year":"2021","unstructured":"Wong W, Brogi E, Reis-Filho JS, et al.. Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. NPJ Breast Cancer. 2021, 7:96. 10.1038\/s41523-021-00302-z","journal-title":"NPJ Breast Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000525324","article-title":"Metaplastic breast cancer: mesenchymal subtype has worse survival outcomes","volume":"17","author":"\u00d6zkurt E","year":"2022","unstructured":"\u00d6zkurt E, Emiro\u011flu S, Cabio\u011flu N, et al.. Metaplastic breast cancer: mesenchymal subtype has worse survival outcomes. Breast Care (Basel). 2022, 17:554-60. 10.1159\/000525324","journal-title":"Breast Care (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-203874","article-title":"Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1","volume":"70","author":"Joneja U","year":"2017","unstructured":"Joneja U, Vranic S, Swensen J, et al.. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J Clin Pathol. 2017, 70:255-9. 10.1136\/jclinpath-2016-203874","journal-title":"J Clin Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00554-x","article-title":"Rare subtypes of triple negative breast cancer: current understanding and future directions","volume":"9","author":"Thomas A","year":"2023","unstructured":"Thomas A, Reis-Filho JS, Geyer CE Jr, Wen HY. Rare subtypes of triple negative breast cancer: current understanding and future directions. NPJ Breast Cancer. 2023, 9:55. 10.1038\/s41523-023-00554-x","journal-title":"NPJ Breast Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28551","article-title":"Metaplastic breast cancer: characteristics and survival outcomes","volume":"14","author":"Thapa B","year":"2022","unstructured":"Thapa B, Arobelidze S, Clark BA, et al.. Metaplastic breast cancer: characteristics and survival outcomes. Cureus. 2022, 14:e28551. 10.7759\/cureus.28551","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3890-4","article-title":"Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis","volume":"22","author":"Nelson RA","year":"2015","unstructured":"Nelson RA, Guye ML, Luu T, Lai LL. Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. Ann Surg Oncol. 2015, 22:24-31. 10.1245\/s10434-014-3890-4","journal-title":"Ann Surg Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01353-z","article-title":"A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations","volume":"22","author":"Reddy TP","year":"2020","unstructured":"Reddy TP, Rosato RR, Li X, Moulder S, Piwnica-Worms H, Chang JC. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Res. 2020, 22:121. 10.1186\/s13058-020-01353-z","journal-title":"Breast Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05264-2","article-title":"Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy","volume":"176","author":"Al-Hilli Z","year":"2019","unstructured":"Al-Hilli Z, Choong G, Keeney MG, Visscher DW, Ingle JN, Goetz MP, Jakub JW. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. Breast Cancer Res Treat. 2019, 176:709-16. 10.1007\/s10549-019-05264-2","journal-title":"Breast Cancer Res Treat"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid P","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al.. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020, 382:810-21. 10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-017-0011-0","article-title":"Dramatic response of metaplastic breast cancer to chemo-immunotherapy","volume":"3","author":"Adams S","year":"2017","unstructured":"Adams S. Dramatic response of metaplastic breast cancer to chemo-immunotherapy. NPJ Breast Cancer. 2017, 3:8. 10.1038\/s41523-017-0011-0","journal-title":"NPJ Breast Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.635237","article-title":"A case series of metastatic metaplastic breast carcinoma treated with anti-PD-1 therapy","volume":"11","author":"Kim I","year":"2021","unstructured":"Kim I, Rajamanickam V, Bernard B, et al.. A case series of metastatic metaplastic breast carcinoma treated with anti-PD-1 therapy. Front Oncol. 2021, 11:635237. 10.3389\/fonc.2021.635237","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2182","article-title":"A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART, SWOG S1609)","volume":"28","author":"Adams S","year":"2022","unstructured":"Adams S, Othus M, Patel SP, et al.. A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART, SWOG S1609). Clin Cancer Res. 2022, 28:271-8. 10.1158\/1078-0432.CCR-21-2182","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357036-triple-negative-metaplastic-breast-cancer-ameliorated-following-keynote-522-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T17:24:40Z","timestamp":1753464280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357036-triple-negative-metaplastic-breast-cancer-ameliorated-following-keynote-522-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.88751","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}